These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22329487)

  • 21. The lantibiotic nukacin ISK-1 exists in an equilibrium between active and inactive lipid-II binding states.
    Fujinami D; -Mahin AA; Elsayed KM; Islam MR; Nagao JI; Roy U; Momin S; Zendo T; Kohda D; Sonomoto K
    Commun Biol; 2018; 1():150. PubMed ID: 30272026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of the nukacin KQU-131, a new type-A(II) lantibiotic produced by Staphylococcus hominis KQU-131 isolated from Thai fermented fish product (Pla-ra).
    Wilaipun P; Zendo T; Okuda K; Nakayama J; Sonomoto K
    Biosci Biotechnol Biochem; 2008 Aug; 72(8):2232-5. PubMed ID: 18685189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nukacin ISK-1, a bacteriostatic lantibiotic.
    Asaduzzaman SM; Nagao J; Iida H; Zendo T; Nakayama J; Sonomoto K
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3595-8. PubMed ID: 19506061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of a gene cluster of Staphylococcus warneri ISK-1 encoding the biosynthesis of and immunity to the lantibiotic, nukacin ISK-1.
    Aso Y; Sashihara T; Nagao J; Kanemasa Y; Koga H; Hashimoto T; Higuchi T; Adachi A; Nomiyama H; Ishizaki A; Nakayama J; Sonomoto K
    Biosci Biotechnol Biochem; 2004 Aug; 68(8):1663-71. PubMed ID: 15322349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete Planomonospora sp.
    Castiglione F; Cavaletti L; Losi D; Lazzarini A; Carrano L; Feroggio M; Ciciliato I; Corti E; Candiani G; Marinelli F; Selva E
    Biochemistry; 2007 May; 46(20):5884-95. PubMed ID: 17469849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bactericidal activity of nukacin ISK-1: an alternative mode of action.
    Roy U; Islam MR; Nagao J; Iida H; Mahin AA; Li M; Zendo T; Nakayama J; Sonomoto K
    Biosci Biotechnol Biochem; 2014; 78(7):1270-3. PubMed ID: 25229869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The biology of lantibiotics from the lacticin 481 group is coming of age.
    Dufour A; Hindré T; Haras D; Le Pennec JP
    FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterologous expression and functional analysis of the gene cluster for the biosynthesis of and immunity to the lantibiotic, nukacin ISK-1.
    Aso Y; Nagao J; Koga H; Okuda K; Kanemasa Y; Sashihara T; Nakayama J; Sonomoto K
    J Biosci Bioeng; 2004; 98(6):429-36. PubMed ID: 16233732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of Ca(2+) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif.
    Böttiger T; Schneider T; Martínez B; Sahl HG; Wiedemann I
    Appl Environ Microbiol; 2009 Jul; 75(13):4427-34. PubMed ID: 19429551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel type of immunity protein, NukH, for the lantibiotic nukacin ISK-1 produced by Staphylococcus warneri ISK-1.
    Aso Y; Okuda K; Nagao J; Kanemasa Y; Thi Bich Phuong N; Koga H; Shioya K; Sashihara T; Nakayama J; Sonomoto K
    Biosci Biotechnol Biochem; 2005 Jul; 69(7):1403-10. PubMed ID: 16041148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies.
    Bonelli RR; Schneider T; Sahl HG; Wiedemann I
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1449-57. PubMed ID: 16569864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting extracellular pyrophosphates underpins the high selectivity of nisin.
    Bonev BB; Breukink E; Swiezewska E; De Kruijff B; Watts A
    FASEB J; 2004 Dec; 18(15):1862-9. PubMed ID: 15576489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation.
    Brötz H; Bierbaum G; Reynolds PE; Sahl HG
    Eur J Biochem; 1997 May; 246(1):193-9. PubMed ID: 9210483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural Insights into the Mode of Action of the Peptide Antibiotic Copsin.
    Franzoi M; van Heuvel Y; Thomann S; Schürch N; Kallio PT; Venier P; Essig A
    Biochemistry; 2017 Sep; 56(37):4992-5001. PubMed ID: 28825809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II.
    Schneider T; Kruse T; Wimmer R; Wiedemann I; Sass V; Pag U; Jansen A; Nielsen AK; Mygind PH; Raventós DS; Neve S; Ravn B; Bonvin AM; De Maria L; Andersen AS; Gammelgaard LK; Sahl HG; Kristensen HH
    Science; 2010 May; 328(5982):1168-72. PubMed ID: 20508130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A lesson in efficient killing from two-component lantibiotics.
    Breukink E
    Mol Microbiol; 2006 Jul; 61(2):271-3. PubMed ID: 16771845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Getting closer to the real bacterial cell wall target: biomolecular interactions of water-soluble lipid II with glycopeptide antibiotics.
    Vollmerhaus PJ; Breukink E; Heck AJ
    Chemistry; 2003 Apr; 9(7):1556-65. PubMed ID: 12658654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the peptide moiety of Lipid II on bacterial transglycosylase.
    Shih HW; Chang YF; Li WJ; Meng FC; Huang CY; Ma C; Cheng TJ; Wong CH; Cheng WC
    Angew Chem Int Ed Engl; 2012 Oct; 51(40):10123-6. PubMed ID: 22952114
    [No Abstract]   [Full Text] [Related]  

  • 39. NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity.
    Hsu ST; Breukink E; Bierbaum G; Sahl HG; de Kruijff B; Kaptein R; van Nuland NA; Bonvin AM
    J Biol Chem; 2003 Apr; 278(15):13110-7. PubMed ID: 12562773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hit 'em where it hurts: The growing and structurally diverse family of peptides that target lipid-II.
    Oppedijk SF; Martin NI; Breukink E
    Biochim Biophys Acta; 2016 May; 1858(5):947-57. PubMed ID: 26523408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.